EXTRAORDINARY Hkkx II—[k.M 3 mi&[k.M (ii) · 2018. 8. 18. · ¹Hkkx II µ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3 iSjkflVkeksy vkbZih 325 fexzk- 13. ,YcsuMktksy $ bojesLVhu xksyh

4770 GI/2018 (1)

jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99

vlk/kj.k EXTRAORDINARY

Hkkx II—[k.M 3—mi&[k.M (ii)

PART II—Section 3—Sub-section (ii)

izkf/dkj ls izdkf'kr

PUBLISHED BY AUTHORITY

la- 3186] ubZ fnYyh] eaxyokj] vxLr 14] [email protected] 23] 1940 No. 3186] NEW DELHI, TUESDAY, AUGUST 14, 2018/SHRAVANA 23, 1940

jlk;u vkSj moZjd ea=ky;

¼vkS"k/k foHkkx½

¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½

vkns’k

ubZ fnYyh] 13 vxLr] 2018

dk-vk- 3982¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼6½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼5½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA

lkj.kh

dz-la-

vuqlwfpr fofufeZfr dk uke@czkaM dk uke

izcyrk bdkbZ fofuekZrk vkSj foi.ku daiuh

[kqnjk ewY; ¼#-½

(1) (2) (3) (4) (5) (6)

1. jkstqokLVkfVu $ DyksfiMksxzsy xksyh

izR;sd gkMZ tsykVkbu xksyh esa% jkstqokLVkfVu dSfY’k;e ds cjkcj jkstqokLVkfVu 10 fexzk-] DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-

1 xksyh eSllZ I;ksj ,aM D;ksj gsYFkds;j izk- fy-@eSllZ ;uhesM VsDuksykWtht fy-

11.70

2. ,eksDlhflfyu $ Dykoqyfud ,flM lLisa’ku

izR;sd 5 fefy- iqufuZfeZr fuyacu esa% ,eksDlhflfyu VªhgkbMªsV vkbZih ds cjkcj ,EyksDlhflfyu 400 fexzk-] iksVsf’k;e DykoqyusV fMyqVsM vkbZih ds cjkcj Dykoqyfud ,flM 75 fexzk- ikykVscqy lLisa’ku D;w,l

1 fefy- eSllZ lsVsd esfMds;j izk- fy-@eSllZ gsxMs ,aM gsxMs QkekZL;wfVdYl ,y,yih

3.01

2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

dyj vizksoM ch dyj ;wtM ou ,Eikmyh dksuVsu LVfjyh okVj QkWj batsD’ku vkbih 30 fefy-

3. vksYeslkVZu $ ,EyksfMikbu $ DyksjFkkfyMksu xksyh

izR;sd fQYe fyfir xksyh esa% vksYeslkVZu esMksDlksfey vkbZih 20 fexzk-] ,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- vkSj DyksjFkkfyMksu vkbZih 12-5 fexzk-

1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ tqosuVl gsYFkds;j fy-

9.30

4. vksYeslkVZu $ ,EyksfMikbu $ DyksjFkkfyMksu xksyh

izR;sd fQYe fyfir xksyh esa% vksYeslkVZu esMksDlksfey vkbZih 40 fexzk-] ,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- vkSj DyksjFkkfyMksu vkbZih 12-5 fexzk-

1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ tqosuVl gsYFkds;j fy-

16.19

5. felksizksLVksy xksyh izR;sd vfyfir xksyh esa% felksizksLVksy vkbZih 25 ,elhth ¼felksizksLVksy 1 izfr’kr fMlij’ku½

1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ tk;Ml gsYFkds;j fy-

4.37

6. felksizksLVksy xksyh izR;sd vfyfir xksyh esa% felksizksLVksy vkbZih 600 ,elhth ¼felksizksLVksy 1 izfr’kr fMlij’ku½

1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ tk;Ml gsYFkds;j fy-

56.93

7. Q~ywukjhtkbu $ izksizkuksyksy xksyh

izR;sd fQYe fyfir xksyh esa% Q~ywukjhtkbu fMgkbMksDyksjkbM chih ds cjkcj Q~ywukjhtkbu 5 fexzk-] izksizkuksyksy gkbMªksDyksjkbM vkbZih 40 fexzk-¼lLVsaM fjfyt esa½

1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl izk- fy-@eSllZ ,CcksV gsYFkds;j izk- fy-

5.39

8. Q~ywukjhtkbu $ izksizkuksyksy xksyh

izR;sd fQYe fyfir xksyh esa% Q~ywukjhtkbu fMgkbMksDyksjkbM chih ds cjkcj Q~ywukjhtkbu 10 fexzk-] izksizkuksyksy gkbMªksDyksjkbM vkbZih 40 fexzk-¼lLVsaM fjfyt esa½

1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl izk- fy-@eSllZ ,CcksV gsYFkds;j izk- fy-

7.20

9. jkstqokLVkfVu $ DyksfiMksxzsy dSIlwy ¼jkstV lhoh½

izR;sd gkMZ tsykVkbu dSIlwy esa% jkstqokLVkfVu dSfY’k;e ds cjkcj jkstqokLVkfVu 10 fexzk- ¼izR;sd fQYe fyfir xksyh esa½] DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼izR;sd fQYe fyfir xksyh esa½

1 dSIlwy eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl izk- fy-@eSllZ MkW- jsM~Mht yscksjsVjht fy-

13.10

10. lsfQDlhe $ Dykoqfyfud ,flM lLisa’ku

izR;sd 5 fefy- iqufuZfeZr fuyacu esa% lsfQDlhe VªhgkbMªsV vkbZih ds cjkcj lsfQDlhe 50 fexzk-] iksVsf’k;e DykoqyusV fMyqVsM vkbZih ds cjkcj Dykoqyfud ,flM 31-25 fexzk- ,DlhisaVl ou ,EikWy ¼,Q,Q,l½ vkWQ LVsfjy okVj QkWj batsD’ku vkbZih 30 fefy-

1 fefy- eSllZ VwouVh QLV lsapwjh QkekZL;wfVdYl izk- fy- @eSllZ XysuekdZ QkekZL;wfVdYl fy-

2.17

11. jkosizktksy $ MkseisfjMksu dSIlwy

izR;sd gkMZ tsykVkbu dSIlwy esa% jkosizktksy lksfM;e vkbZih 40 ¼jsMfM’k czkmu ,uVsfjd fyfir iSysVl½] MkseisfjMksu vkbZih 30 fexzk- ¼vkWjsat dyMZ lLVsaM fjfyt iSysVl½

1 dSIlwy eSllZ foaMykl ck;ksVsd fy-@eSllZ dSfMyk QkekZL;wfVdYl fy-

8.46

12. ,lhDyksQsud $ iSjkflVkeksy xksyh ¼DyksusV½

izR;sd vfyfir xksyh esa% ,lhDyksQsud vkbZih 100 fexzk-]

1 xksyh eSllZ cusZV QkekZL;wfVdYl izk- fy-

3.27

¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3

iSjkflVkeksy vkbZih 325 fexzk-

13. ,YcsuMktksy $ bojesLVhu xksyh ¼chbZ,u$½

izR;sd vfyfir fMlijlscy xksyh esa% ,YcsuMktksy vkbZih 400 fexzk- bojesLVhu vkbZih 6 fexzk-

1 xksyh eSllZ cusZV QkekZL;wfVdYl izk- fy-

17.48

14. flYuhfMikbu $ esVksizksyksy xksyh

izR;sd fQYe fyfir foys;MZ xksyh esa% flYuhfMikbu vkbZih 10 fexzk-] esVksizksyksy lqlkbusV vkbZih ds cjkcj esVksizksyksy VkjVªsV 50 fexzk- ¼,DlVsaM fjfyt QkWeZ esa½

1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@ eSllZ esudkbaM QkekZ fy-

7.346

15. ,VksjokLVkfVu $ DyksfiMksxzsy dSIlwy ¼tqfcdksM lhoh 10½

izR;sd gkMZ tsykVkbu dSIlwy esa% ,VksjokLVkfVu dSfY’k;e vkbZih ds cjkcj ,VksjokLVkfVu 10 fexzk- ¼fQYe fyfir xksyh esa½] DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼nks fQYe fyfir xksyh esa½

1 dSIlwy eSllZ foaMykl ck;ksVsd izk- fy-@eSllZ tqfcysaV ykbQ lkbaflt fy-

8.234

16. ,VksjokLVkfVu $ DyksfiMksxzsy dSIlwy ¼tqfcdksM lhoh 20½

izR;sd gkMZ tsykVkbu dSIlwy esa% ,VksjokLVkfVu dSfY’k;e vkbZih ds cjkcj ,VksjokLVkfVu 20 fexzk- ¼fQYe fyfir xksyh esa½] DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼nks fQYe fyfir xksyh esa½

1 dSIlwy eSllZ foaMykl ck;ksVsd izk- fy-@eSllZ tqfcysaV ykbQ lkbaflt fy-

13.30

17. VsyfelkVZu $ DyksjFkkyhMksu xksyh ¼Vsyfetqc lh,p 40½

izR;sd vfyfir fcys;j xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] DyksjFkkyhMksu vkbZih 12-50 fexzk- xksyh

1 xksyh eSllZ gsVsjks yscl izk- fy-@eSllZ tqfcysaV ykbQ lkbaflt fy-

7.92

18. VsyfelkVZu $ DyksjFkkyhMksu xksyh ¼Vsyfetqc lh,p 80½

izR;sd vfyfir fcys;j xksyh esa% VsyfelkVZu vkbZih 80 fexzk-] DyksjFkkyhMksu vkbZih 12-50 fexzk- xksyh

1 xksyh eSllZ gsVsjks yscl izk- fy-@eSllZ tqfcysaV ykbQ lkbaflt fy-

13.82

19. iSjkflVkeksy $ QsuhysQzhu $ dSQhu $ fMQsugkbMªkekbu xksyh

izR;sd vfyfir xksyh esa% iSjkflVkeksy vkbZih 500 fexzk-] QsuhysQzhu gkbMªksDyksjkbM vkbZih 5 fexzk-] dSQhu ¼,ugkbMªkst½ vkbZih 30 fexzk-] fMQsugkbMªkekbu gkbMªksDyksjkbM vkbZih 25 fexzk-

1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@ eSllZ ,CcksV gsYFkds;j izk- fy-

3.06

20 fXyDyktkbM $ esVQksfeZu xksyh

izR;sd vfyfir xksyh esa% fXyDyktkbM vkbZih 60 fexzk- ¼,DlVsaM fjfyt QkWeZ esa½] esVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk- ¼,DlVsaM fjfyt QkWeZ esa½

1 xksyh eSllZ esfMQkslZ gsYFkds;j izk- fy-@eSllZ esudkbaM QkekZ fy-

8.38

21. XyhesihjkbM $ esVQksfeZu xksyh

izR;sd vfyfir fcys;MZ xksyh esa% XyhesihjkbM vkbZih 0-5 fexzk-] esVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk-¼lLVsaM fjfyt QkWeZ½

1 xksyh eSllZ esfMQkslZ gsYFkds;j izk- fy-@eSllZ esudkbaM QkekZ fy-

3.77

22. ,VksjokLVkfVu $ DyksfiMksxzsy dSIlwy

izR;sd gkMZ tsykVkbu dSIlwy esa% ,VksjokLVkfVu dSfY’k;e vkbZih ds cjkcj ,VksjokLVkfVu 10 fexzk- ¼iSysVl esa½] DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75

1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@ eSllZ esudkbaM QkekZ fy-

8.394


fexzk- ¼iSysVl esa½

23. ,VksjokLVkfVu $ DyksfiMksxzsy dSIlwy

izR;sd gkMZ tsykVkbu dSIlwy esa% ,VksjokLVkfVu dSfY’k;e vkbZih ds cjkcj ,VksjokLVkfVu 20 fexzk- ¼iSysVl esa½] DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼iSysVl esa½

1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@ eSllZ esudkbaM QkekZ fy-

10.596

24. lksQksLcqohj $ osyirkLohj xksyh

izR;sd fQYe vfyfir xksyh esa% lksQksLcqohj 400 fexzk-] osyirkLohj 100 fexzk-

28 xksyh eSllZ ukVdks QkekZ fy-@ eSllZ ,CcksV bafM;k fy-

15481.86

25. fMlkbDyksekbu gkbMªksDyksjkbM xksyh

izR;sd vfyfir xksyh% fMlkbDyksekbu gkbMªksDyksjkbM vkbZih 20 fexzk-

1 xksyh eSllZ dksuVsLV dSfedYl fy-

0.85

26. VªkLVqtqec batsD’ku izR;sd dkWEch fdV esa% ,½ izR;sd y;ksfQfytsM ok;y esa VªkLVqtqec vkbZ,p,l 150 fexzk-] ,] ,YQk Vªsgykst fMgkbMªsV 136-2 fexzk-] ,y&fglVhMkbu ,plh,y 3-36 fexzk-] ,y&fglVhMkbu 2-16 fexzk-] ikWyhlkscsZV 20 ;w,lih 0-6 fexzk-] ch½ izR;sd LVsjkby MCY;w,QvkbZ ok;y esa LVsjkby okVj QkWj batsD’ku vkbZih 10 fefy-

izfr iSd eSllZ fjyk;al ykbQ lkbalst izk- fy-@eSllZ yqfiu fy-

18400.89

27. VªkLVqtqec batsD’ku izR;sd dkWEch fdV esa% ,½ izR;sd y;ksfQfytsM ok;y esa VªkLVqtqec vkbZ,p,l 150 fexzk-] ,] ,YQk Vªsgykst fMgkbMªsV 136-2 fexzk-] ,y&fglVhMkbu ,plh,y 3-36 fexzk-] ,y&fglVhMkbu 2-16 fexzk-] ikWyhlkscsZV 20 ;w,lih 0-6 fexzk-] ch½ izR;sd LVsjkby MCY;w,QvkbZ ok;y esa LVsjkby okVj QkWj batsD’ku vkbZih 10 fefy-

izfr iSd eSllZ MkW- jsM~Mht yscksjsVjht fy-

18125.00

28. cqMslksukbM jsliYl 0-5 fexzk-@2fefy- ¼lLisa’ku QkWj uscqykbts’ku½

izR;sd 2 fefy- fjliysl esa% cqMslksukbM vkbZih 0-5 fexzk-

2 fefy- iSd

eSllZ lu QkekZL;wfVdYl esfMds;j fy-@eSllZ lu QkekZ yscksjsVjht fy-

17.59

29. jkstqokLVkfVu $ ,fLifju $ DyksfiMksxzsy dSIlwy ¼lqyVkfVu xksYM½

izR;sd gkMZ tsykVkbu dSIlwy esa% jkstqokLVkfVu dSfY’k;e ds cjkcj jkstqokLVkfVu 10 fexzk- ¼iSysVl esa½] ,fLifju vkbZih 75 fexzk- ¼vkarfjd fyfir iSysVl esa½ DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-¼iSysVl esa½

1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@ eSllZ esMksQkekZ

11.53

30. Qsjl ,LdkscsZV $ Qksfyd ,flM MªksIl ¼VªhQj $ ,DlVh½

izR;sd fefy- MªksIl esa% Qsjl ,LdkscsZV ds cjkcj bysesuVy vk;ju 10 fexzk-] Qksfyd ,flM vkbZih 100 ,elhth

1 fefy- eSllZ ,isDl yscksjsVjht izk- fy-

3.58


31. VªkLVqtqeo batsD’ku izR;sd dkWEch fdV esa% ,½ izR;sd y;ksfQfytsM ok;y esa VªkLVqtqec vkbZ,p,l 150 fexzk-] ,] ,YQk Vªsgykst fMgkbMªsV 136-2 fexzk-] ,y&fglVhMkbu ,plh,y 3-36 fexzk-] ,y&fglVhMkbu 2-16 fexzk-] ikWyhlkscsZV 200-6 fexzk-] ch½ izR;sd LVsjkby MCY;w,QvkbZ ok;y esa LVsjkby okVj QkWj batsD’ku vkbZih 10 fefy-

izfr iSd eSllZ fjyk;al ykbQ lkbalst izk- fy-@eSllZ vkjihth ykbQ lkbalst fy-

18125.00

32. QksjeksVsjksy $ cqMslksukbM lLisa’ku ¼QkseVkbM 0-5½

izR;sd 2 fefy- fjliysl esa% QksjeksVsjksy QqekjsV fMgkbMªsV vkbZih ds cjkcj QksjeksVsjksy QqekjsV 20 ,elhth] cqMslksukbM vkbZih 0-5 fexzk-

2 fefy- iSd


35.04

33. QksjeksVsjksy $ cqMslksukbM lLisa’ku ¼QkseVkbM 1½

izR;sd 2 fefy- fjliysl esa% QksjeksVsjksy QqekjsV fMgkbMªsV vkbZih ds cjkcj QksjeksVsjksy QqekjsV 20 ,elhth] cqMslksukbM vkbZih 1 fexzk-

2 fefy- iSd


40.96

34. fjdksefcuaV g~;qeu dksfj;ksfud xksukMksVªksfiu QkWj batsD’ku

izR;sd ih,Q,l esa% fjdksefcuaV g~;qeu dksfj;ksfud xksukMksVªksfiu QkWj batsD’ku 6500 vkbZ;w

izfr iSd eSllZ Hkkjr lsje ,aM oSDlhu fy-

1294.64

35. VsyfelkVZu $ ,EyksfMikbu $ DyksjFkkyhMksu xksyh ¼VªhVsylkj 80 ,p,l½

izR;sd fQYe fyfir xksyh esa% VsyfelkVZu 80 fexzk- ,EyksfMikbu 5 fexzk-] DyksjFkkyhMksu 12-5 fexzk-

1 xksyh eSllZ thds,e U;w QkekZ@ eSllZ ;wuhdse yscksjsVjht fy-

13.76

36. vksYeslkVZu $ ,EyksfMikbu $ DyksjFkkyhMksu xksyh ¼Vªh;ksVsylkj 20 ,p,l½

izR;sd fQYe fyfir xksyh esa% vksYeslkVZu esMksDlksfey 20 fexzk-] ,EyksfMikbu 5 fexzk-] DyksjFkkyhMksu 12-5 fexzk-


9.25

37. vksYeslkVZu $ ,EyksfMikbu $ DyksjFkkyhMksu xksyh ¼Vªh;ksVsylkj 40 ,p,l½

izR;sd fQYe fyfir xksyh esa% vksYeslkVZu esMksDlksfey 40 fexzk-] ,EyksfMikbu 5 fexzk-] DyksjFkkfyMksu 12-5 fexzk-


16.70

38. VsyfelkVZu $ ,EyksfMikbu $ DyksjFkkyhMksu xksyh ¼VªhVsylkj 40 ½

izR;sd fQYe fyfir xksyh esa% VsyfelkVZu 40 fexzk-] ,EyksfMikbu 5 fexzk-] DyksjFkkyhMksu 6-25 fexzk-


8.35

39. VsyfelkVZu $ ,EyksfMikbu $ DyksjFkkyhMksu xksyh ¼VªhVsylkj 40 ,p,l½



9.37

40. VsyfelkVZu $ ,EyksfMikbu $ DyksjFkkyhMksu xksyh ¼VªhVsylkj 80½



14.47


41. MkWDlhlkbfDyu $ ySfDVd ,flM cSflyl dSIlwy

izR;sd gkMZ tsykVkbu dSIlwy esa% MkWDlhlkbfDyu gkbDysV vkbZih ds cjkcj MkWDlhlkbfDyu 100 fexzk-] ySfDVd ,flM cSflyl 5 fcfy;u Liksjsl

1 dSIlwy eSllZ csusV QkekZL;wfVdYl fy-

4.96

42. jkstqokLVkfVu $ DyksfiMksxzsy $ ,fLifju dSIlwy


1 dSIlwy eSllZ l;kuksdse QkekZL;wfVdYl fy-@eSllZ ,ifjdk gsYFkds;j izk- fy-

11.53

43. jkstqokLVkfVu $ DyksfiMksxzsy $ ,fLifju dSIlwy


1 dSIlwy eSllZ l;kuksdse QkekZL;wfVdYl fy-@eSllZ ,ifjdk gsYFkds;j izk- fy-

17.88

44. esekuVkbu $ Mksusisttkby xksyh

izR;sd fQYe fyfir xksyh esa% esekuVkbu gkbMªksDyksjkbM ;w,lih 5 fexzk-] Mksusisttkby gkbMªksDyksjkbM vkbZih 5 fexzk-

1 xksyh eSllZ fFk;ksu QkekZL;wfVdYl fy-@eSllZ beD;ksj QkekZL;wfVdYl fy-

9.93

45. esekuVkbu $ Mksusisttkby xksyh

izR;sd fQYe fyfir xksyh esa% esekuVkbu gkbMªksDyksjkbM ;w,lih 10 fexzk-] Mksusisttkby gkbMªksDyksjkbM vkbZih 5 fexzk-

1 xksyh eSllZ fFk;ksu QkekZL;wfVdYl fy-@ eSllZ beD;ksj QkekZL;wfVdYl fy-

12.56

46. flYuhfMikbu $ VsyfelkVZu xksyh

izR;sd fQYe fyfir xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] flYuhfMikbu 10 fexzk-

1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@ eSllZ ,CcksV gsYFkds;j izk- fy-

7.77

47. gk;kslkbu cqVkbczksekbM $ esQsukfed ,flM xksyh

izR;sd fQYe fyfir xksyh esa% gk;kslkbu cqVkbczksekbM vkbZih 10 fexzk-] esQsukfed ,flM xksyh vkbZih 250 fexzk-

1 xksyh eSllZ tk;Ml gsYFkds;j fy-

8.99

48. jkstqokLVkfVu $ ,fLifju $ DyksfiMksxzsy dSIlwy ¼jkslqfyi xksYM 10½


1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@ eSllZ fliyk fy-

11.53

49. jkstqokLVkfVu $ ,fLifju $ DyksfiMksxzsy dSIlwy ¼jkslqfyi xksYM 20½


1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@ eSllZ fliyk fy-

17.88

50. jkstqokLVkfVu $ ,fLifju $ DyksfiMksxzsy dSIlwy ¼;wuhLVkj xksYM 10@75½

izR;sd gkMZ tsykVkbu dSIlwy esa% jkstqokLVkfVu dSfY’k;e ds cjkcj jkstqokLVkfVu 10 fexzk- ¼iSysVl esa½] ,fLifju vkbZih 75 fexzk- ¼vkarfjd fyfir iSysVl esa½

1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@ eSllZ VkWjsZaV QkekZL;wfVdYl fy-

11.53


DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-¼iSysVl esa½

51. jkstqokLVkfVu $ ,fLifju $ DyksfiMksxzsy dSIlwy ¼;wuhLVkj xksYM 20@75½


1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@ eSllZ VkWjsZaV QkekZL;wfVdYl fy-

17.88

52. XyhesfijkbM $ esVQksfeZu ,plh,y xksyh

izR;sd vfyfir fcys;MZ xksyh esa% XyhesihjkbM vkbZih 0-5 fexzk-] esVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk-¼izksykWxM fjfyt QkWeZ½

1 xksyh eSllZ foaMykl ck;ksVsd izk- fy-@eSllZ XysuekdZ QkekZL;wfVdYl fy-

3.77

53. VsyfelkVZu $ esVksizksyksy xksyh ¼Vsyfeizkbe chVk 25½

izR;sd lLVsu fjfyt xksyh esa% VsyfelkVZu 40 fexzk-] esVksizksyksy 25 fexzk-

1 xksyh eSllZ ck;ksyVl QkekZL;wfVdYl izk- fy-@ eSllZ izhel jsfefMt izk- fy-

7.58

54. VsyfelkVZu $ esVksizksyksy xksyh ¼Vsyfeizkbe chVk 50½

izR;sd lLVsu fjfyt xksyh esa% VsyfelkVZu 40 fexzk-] esVksizksyksy 50 fexzk-

1 xksyh eSllZ ck;ksyVl QkekZL;wfVdYl izk- fy-@ eSllZ izhel jsfefMt izk- fy-

9.10

55. ,VksjokLVkfVu $ DyksfiMksxzsy $ ,fLifju dSIlwy

izR;sd gkMZ tsykVkbu dSIlwy esa% ,VksjokLVkfVu dSfY’k;e vkbZih ds cjkcj ,VksjokLVkfVu 20 fexzk- ¼iSysVl esa½] ,fLifju vkbZih 75 fexzk- ¼vkarfjd fyfir iSysVl esa½ DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼iSysVl esa½

1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@ eSllZ tk;Ml gsYFkds;j fy- ,aM eSllZ VªhLVkj QkWeqZys’ku izk- fy-@eSllZ tk;Ml gsYFkds;j fy-

5.22

56. ,VksjokLVkfVu $ DyksfiMksxzsy $ ,fLifju dSIlwy

izR;sd gkMZ tsykVkbu dSIlwy esa% ,VksjokLVkfVu dSfY’k;e vkbZih ds cjkcj ,VksjokLVkfVu 10 fexzk- ¼iSysVl esa½] ,fLifju vkbZih 75 fexzk- ¼vkarfjd fyfir iSysVl esa½ DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼iSysVl esa½

1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ tk;Ml gsYFkds;j fy- ,aM eSllZ VªhLVkj QkWeqZys’ku izk- fy-@eSllZ tk;Ml gsYFkds;j fy-

3.86

57. esfFkydksckykfeu $ esVQksfeZu xksyh ¼XykbdksesV 500 ,elh½

izR;sd fQYe fyfir xksyh esa% esVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk-¼,lvkj QkWeZ½ esfFkydksckykfeu ts-ih- 750 ,elhth

1 xksyh eSllz ,svkWu QkWeqZys’ku izk- fy-@eSllZ ;wlhoh izk- fy-

5.45

58. esfFkydksckykfeu $ esVQksfeZu xksyh ¼fxykbdksesV 1000 ,elh½

izR;sd fQYe fyfir xksyh esa% esVQksfeZu gkbMªksDyksjkbM vkbZih 1000 fexzk-¼,lvkj QkWeZ½ esfFkydksckykfeu ts-ih- 750 ,elhth

1 xksyh eSllz ,svkWu QkWeqZys’ku izk- fy-@eSllZ ;wlhoh izk- fy-

7.97

59. Qsjl ,LdkscsZV $ Qksfyd ,flM $ ftad lYQsV xksyh ¼izksfodksu&Qh½

izR;sd fQYe fyfir xksyh esa% Qsjl ,LdkscsZV ds cjkcj bysesuVy vk;ju 100 fexzk-] Qksfyd ,flM vkbZih 1-5 fexzk-] ftad lYQsV eksuksgkbMªsV ds cjkcj bysesuVy ftad 22-5 fexzk-

1 xksyh eSllZ QkekZQsczhdksu 6.22


60. Qsjl ,LdkscsZV $ Qksfyd ,flM lLisa’ku ¼izksfodksu&Qh½

izR;sd fefy- esa*% Qsjl ,LdkscsZV ds cjkcj bysesuVy vk;ju 30 fexzk-+] Qksfyd ,flM vkbZih 500 ,elhth

1 fefy- eSllZ QkekZQsczhdksu 0.744

61. ,lhyksQsud $ iSjkflVkeksy xksyh ¼fousl½½

izR;sd fQYe fyfir xksyh esa% ,dsyksQsud vkbZih 100 fexzk-] iSjkflVkeksy vkbZih 235 fexzk-

1 xksyh eSllZ fcaMykl ck;ksVsd izk- fy-@eSllZ fou esMds;j izk- fy-

3.34

62. fMDyksQsud lksfM;e batsD’ku

izR;sd fefy- batsD’ku esa% fMDyksQsud lksfM;e vkbZih 75 fexzk-] okWVj QkWj batsD’ku vkbZih D;w,l

1 fefy- iSd

eSllz csusV QkekZL;wfVdYl fy-

20.00

63. VsyfelkVZu $ ,EyksfMikbu $ DyksjFkkyhMksu xksyh ¼lhVhMh&Ve 6-25@40@5½

izR;sd fQYe fyfir xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] ,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk-] DyksjFkkyhMksu vkbZih 6-25 fexzk-

1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ bidk yscksjsVjht fy-

8.62




8.75




14.40




14.00

67. VsyfelkVZu $ ,EyksfMikbu $ DyksjFkkyhMksu xksyh ¼Vsyokl 3 Mh lhVh 40½


1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ ,fjLVks QkekZL;wfVdYl izk- fy-

14.12

68. VsyfelkVZu $ ,EyksfMikbu $ DyksjFkkyhMksu xksyh ¼Vsyokl 3 Mh lhVh 40½


1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ ,fjLVks QkekZL;wfVdYl izk- fy-

8.91

69. VsyfelkVZu $ flYuhfMikbu $ DyksjFkkyhMksu xksyh ¼lhVhMh&Vhlh 6-25½

izR;sd fQYe fyfir xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] flYuhfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk-] DyksjFkkyhMksu vkbZih 6-25 fexzk-

1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ bidk yscksjsVjht fy-

10.16

70. ihbZth ,y & ,sLiSjtkbusl batsD’ku

izR;sd 5 fefy- ok;y batsD’ku esa% ihbZth ,y & ,sLiSjtkbusl batsD’ku 750 vkbZ;w@fefy-

5 fefy-@ok;y

eSllZ fojpkso ck;ksVsd izk- fy-@eSllZ dSfMyk QkekZL;wfVdYl fy-

38730.74

71. ihbZth ,y & ,sLiSjtkbusl batsD’ku

izR;sd 5 fefy- ok;y batsD’ku esa% ihbZth ,y & ,sLiSjtkbusl batsD’ku 750 vkbZ;w@fefy-

5 fefy-@ok;y

eSllZ dSfMyk gsYFkds;j fy-

38730.74

72. Qsjl ,LdkscsZV $ Qksfyd ,flM $ l;kuksdksckyfeu $ ikbjhMkWfDlu $ dksysDylhQsjksy xksyh

izR;sd fQYe fyfir xksyh esa% Qsjl ,LdkscsZV ds cjkcj bysesuVy vk;ju 100 fexzk-] Qksfyd ,flM vkbZih 1-5 fexzk-] l;kuksdksckyfeu ¼foVkfeu ch12½ vkbZih 7-5 ,elhth] ikbjhMkWfDlu gkbMªksDyksjkbM

1 xksyh eSllZ fr:ifr esfMds;j fy-@eSllZ dSfMyk gsYFkds;j fy-

9.44


¼foVkfeu ch6½ vkbZih 1-5 fexzk-] dksysDylhQsjksy ¼foVkfeu Mh3½ vkbZih 1000 vkbZ;w

uksV %

¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA

¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA

¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA

¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA

¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fu/kkZfjr lHkh ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr tSlk fd dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr [email protected] dEifu;ka tks vuqikyu djrh gSA

¼p½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼N½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsA

[dka- la-@191@59/2018@,Q@Qk- la- 8¼59½@2018@Mhih@,uihih,&fMoh-II]

cythr flag] lgk;d funs'kd

MINISTRY OF CHEMICALS AND FERTILIZERS

(Department of Pharmaceuticals)

(National Pharmaceutical Pricing Authority)

ORDER

New Delhi, the 13th August, 2018

S.O. 3982(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices

Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March,

2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National

Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in

column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation

to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit

and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4)

and (5) thereof;


TABLE

Sl.

No.

Name of the

Formulation / Brand

Name

Strength Unit Manufacturer &

Marketing Company

Retail

Price

(Rs.)

(1) (2) (3) (4) (5) (6)

1. Rosuvastatin +

Clopidogrel Tablet

Each film coated tablet contains:

Rosuvastatin Calcium IP eq. to

Rosuvastatin 10mg,

Clopidogrel Bisulphate IP eq. to

Clopidogrel 75mg.

1 Tablet M/s Pure and Cure

Healthcare Pvt. Ltd. /

M/s Unimed

Technologies Ltd.

11.70

2. Amoxicillin +

Clavulanic Acid

Suspension

Each 5ml of reconstituted suspension

contains:

Amoxicillin Trihydrate IP eq. to

Amoxyiillin 400mg,

Potassium Clavulante Diluted IP eq.

to Clavulanic Acid 57mg In a

Palatable suspension q.s. Color

Approved colour used B One

Ampoule Contain Sterile Water for

Injection IP 30ml

1 ML M/s Saitech Medicare

Pvt. Ltd.

/ M/s Hegde & Hegde

Pharmaceutical LLP

3.01

3. Olmesartan

+Amlodipine +

Chlorthalidone Tablet


Olmesartan Medoxomil IP 20mg,

Amlodipine Besylate IP eq. to

Amlodipine 5mg &

Chlorthalidone IP 12.5mg

1 Tablet M/s Synokem

Pharmaceuticals Limited

/ M/s Zuventus

Healthcare Limited

9.30

4. Olmesartan

+Amlodipine +



Olmesartan Medoxomil IP 40mg,


Amlodipine 5mg &



Pharmaceuticals / M/s

Zuventus Healthcare

Limited

16.19

5. Misoprostol Tablet Each uncoated tablets contains:

Misoprostol IP 25mcg (As

Misoprostol 1% Dispersion)



/ M/s Zydus Healthcare

Limited

4.37

6. Misoprostol Tablet Each uncoated tablets contains:

Misoprostol IP 600mcg (As

Misoprostol 1% Dispersion)



/ M/s Zydus Healthcare

Limited

56.93

7. Flunarizine +

Propranolol tablet

Each uncoated bilayered tablet

contains:

Flunarizine Dihydrochloride BP eq.

to Flunarizine 5mg,

Propranolol Hydrochloride IP 40mg

(As Sustained Release)

1 Tablet M/s Akums Drugs and

Pharmaceuticals Pvt.

Ltd. / M/s Abbott

Healthcare Pvt. Ltd.

5.39

8. Flunarizine +

Propranolol tablet


contains:

Flunarizine Dihydrochloride BP eq.

to Flunarizine 10mg,

Propranolol Hydrochloride IP 40mg

(As Sustained Release)



Ltd. / M/s Abbott

Healthcare Pvt. Ltd.

7.20

9. Rosuvastatin +

Clopidogrel capsule

Each hard Gelatin capsule contains:

Rosuvastatin Calcium IP eq. to

1

Capsule

M/s Akums Drugs and


13.10


(Rozat CV) Rosuvastatin 10mg (As film coated

form tablet),


Clopidogrel 75mg (As film coated

tablet form)

Ltd. / M/s Dr. Reddy’s

Laboratories Limited

10. Cefixime +

Clavulanic Acid

suspension

Each 5ml of reconstituted

Suspension contains:

Cefixime Trihydrate IP eq. to

Cefixime 50mg,

Potassium Clavulanate Diluted IP eq.

to Clavulanic Acid 31.25mg

Excipients.

One Ampoule (FFS) of Sterile water

for Injection IP 30ml

1 ML M/s Twenty First

Century Pharmaceuticals

Pvt. Ltd. / M/s

Glenmark

Pharmaceuticals Ltd.

2.17

11. Rabeprazole +

Domperidone Capsule

Each hard gelatine capsule contains:

Rabeprazole Sodium IP 40mg (As

Reddish brown enteric coated

pellets)

Domperidone IP 30mg (As orange

coloured sustained released pallets)

1

Capsule

M/s Windlas Biotech

Ltd. / M/s Cadila


8.46

12. Aceclofenac +

Paracetamol Tablet

(CLONET )

Each Uncoated tablet contains:

Aceclofenac IP 100mg,

Paracetamol IP 325mg

1 Tablet M/s Burnet


Ltd.

3.27

13. Albendazole +

Ivermectin Tablet

(BEN +)

Each uncoated dispersible tablet

contains:

Albendazole IP 400mg,

Ivermectin IP 6mg

1 Tablet M/s Burnet


Ltd.

17.48

14. Cilnidipine +

Metoprolol tablet

Each film coated bilayered tablet

contains:

Cilnidipine IP 10mg,

Metoprolol Succinate IP eq. to

Metoprolol Tartrate 50mg (In

extended release form)


Pharmaceuicals Ltd. /

M/s Mankind Pharma

Ltd.

7.346

15. Atorvastatin +

Clopidogrel capsule

(Jubicoad CV 10)


Atorvastatin Calcium IP eq. to

Atorvastatin 10mg (As film coated

tablets)


Clopidogrel 75mg (As two film

coated tablets)

1

Capsule

M/s Windlas Biotech

Pvt. Ltd. / M/s Jubilant

Life Sicences Limited

8.234

16. Atorvastatin +

Clopidogrel capsule

(Jubicoad CV 20)



Atorvastatin 20mg (As film coated

tablets)


Clopidogrel 75mg (As two film

coated tablets)

1

Capsule

M/s Windlas Biotech

Pvt. Ltd. / M/s Jubilant

Life Sicences Limited

13.30

17. Telmisartan +

Chlorthalidone tablet

(Telmijub CH 40)

Each Uncoated bilayer tablet

contains:

Telmisartan IP 40mg,

Chlorthalidone IP 12.50mg Tablets

1 Tablet M/s Hetero Labs Pvt.

Ltd. / M/s Jubilant Life

Sciences Limited

7.92


18. Telmisartan +

Chlorthalidone tablet

(Telmijub CH 80)

Each Uncoated bilayer tablet

contains:

Telmisartan IP 80mg +

Chlorthalidone IP 12.50mg Tablet

1 Tablet M/s Hetero Labs Pvt.

Ltd. / M/s Jubilant Life

Sciences Limited

13.82

19. Paracetamol +

Phenylephrine +

Caffeine +

Diphenhydramine

Tablet

Each uncoated tablet contains:

Paracetamol IP 500mg

Phenylephrine Hydrochloride IP

5mg,

Caffeine (Anhydrous) IP 30mg,

Diphenhydramine Hydrochloride IP

25mg

1 Tablet M/s Akums Drugs &

Pharmaceuticals Ltd. /

M/s Abbott Healthcare

Pvt. Ltd.

3.06

20 Gliclazide +

Metformin tablet


Gliclazide IP 60mg (in extended

release form)

Metformin Hydrochloride IP 500mg

(in extended release form)

1 Tablet M/s Mediforce


M/s Mankind Pharma

Limited

8.38

21. Glimepiride +

Metformin tablet


contains:

Glimepiride IP 0.5mg


(in sustained release form)

1 Tablet M/s Mediforce


M/s Mankind Pharma

Limited

3.77

22. Atorvastatin +

Clopidogrel Capsule



Atorvastatin 10mg (As pellets)


Clopidogrel 75mg (As pellets)

1

Capsule

M/s Synokem


M/s Mankind Pharma

Limited

8.394

23. Atorvastatin +

Clopidogrel Capsule



Atorvastatin 20mg (As pellets)


Clopidogrel 75mg (As pellets)

1

Capsule

M/s Synokem


M/s Mankind Pharma

Limited

10.596

24. Sofosbuvir +

Velpatasvir tablet


Sofosbuvir 400mg,

Velpatasvir 100mg

28’s

Tablets

M/s Natco Pharma

Limited / M/s Abbott

India Limited

15481.86

25. Dicyclomine

Hydrochloride Tablet


Dicyclomine Hydrochloride IP 20

mg

1 Tablet M/s Kontest Chemicals

Ltd.

0.85

26. Trastuzumab

Injection

Each combi kit contains

A) Each Lyophilized vial containing

Trastuzumab IHS 150 mg,

A,α trehalose dihydrate 136.2 mg,

L-Histidine HCL 3.36 mg,

L-Histidine 2.16 mg,

Polysorbate 20 0.6 mg

B) Each sterile WFI vial containing

Sterile water for injection IP 10 ml

Per Pack M/s Reliance

Lifesciences Pvt. Ltd. /

M/s Lupin Ltd,

18400.89

27. Trastuzumab

Injection




Per Pack Dr. Reddy’s

Laboratories Ltd.

18125.00








28. Budesonide respules

0.5mg/2ml

(suspension for

nebulisation)

Each 2 ml respules contains:

Budesonide IP 0.5 mg

2 ml

Pack

M/s Sun Pharmaceutical

Medicare Ltd. / M/s Sun

Pharma Laboratories

Ltd.

17.59

29. Rosuvastatin +

Aspirin +

Clopidogrel Capsule

(Sultatin Gold)

Each hard gelatin capsule containing

Rosuvastatin Calcium eq to

Rosuvastatin 10mg (as pellets)

Aspirin IP 75 mg (as enteric coated

pellets)

Clopidogrel Bisulphate IP eq to

Clopidogrel 75 mg (as pellets)

1

Capsule

M/s Synokem


M/s Medopharm

11.53

30. Ferrous Ascorbate +

Folic acids drops

(Trifer – XT)

Each ml drops contains:

Ferrous Ascorbate eq to elemental

iron 10mg

Folic Acid IP 100mcg

1 ML M/s Apex laboratories

Pvt. Ltd.

3.58

31. Trastuzumab

Injection










Per Pack M/s Reliance Life

Sciences Pvt. Ltd. / M/s

RPG Life Sciences Ltd.

18125.00

32. Formoterol +

Budesonide

Suspension

(Fomtide 0.5)


Formoterol Fumarate Dihydrate IP

eq. to Formoterol Fumarate 20 mcg

Budesonide IP 0.5 mg

2 ML

Pack



Pharma Laboratories Ltd

35.04

33. Formoterol +

Budesonide

Suspension

(Fomtide 1)


Formoterol Fumarate Dihydrate IP

eq to Formoterol Fumarate 20mcg

Budesonide IP 1 mg

2 ML

Pack



Pharma Laboratories Ltd

40.96

34. Recombinant Human

Chorionic

Gonadotropin for

Injection

Each PFS containing

Recombinant Human Chorionic

Gonadotropin for Injection 6500IU

Each

Pack

M/s Bharat Serums and

Vaccines Ltd.

1294.64

35. Telmisartan +

Amlodipine +

Chlorthalidone

Tablet

(Tritelsar 80 HS)


Telmisartan IP 80mg


Amlodipine 5mg


1 Tablet M/s GKM New Pharma /

M/s Unichem

Laboratories Limited.

13.76

36. Olmesartan +

Amlodipine +

Chlorthalidone


Olmesartan Medoxomil IP 20mg


M/s Unichem

9.25


Tablet

(Triolsar 20 HS)


Amlodipine 5mg



37. Olmesartan +

Amlodipine +

Chlorthalidone

Tablet

(Triolsar 40 HS)


Olmesartan Medoxomil IP 40mg


Amlodipine 5mg

Chlorthalidone IP12.50mg


M/s Unichem


16.70

38. Telmisartan +

Amlodipine +

Chlorthalidone

Tablet

(Tritelsar 40)


Telmisartan IP 40mg


Amlodipine 5mg



M/s Unichem


8.35

39. Telmisartan +

Amlodipine +

Chlorthalidone

Tablet

(Tritelsar 40 HS)


Telmisartan IP 40mg


Amlodipine 5mg



M/s Unichem


9.37

40. Telmisartan +

Amlodipine +

Chlorthalidone

Tablet

(Tritelsar 80)


Telmisartan IP 80mg


Amlodipine 5mg



M/s Unichem


14.47

41. Doxycycline + Lactic

acid bacillus Capsules

Each hard gelatin capsules

containing

Doxycycline Hyclate IP eq to

Doxycycline 100 mg

Lactic Acid Bacillus 5 billion spores

1

Capsule

M/s Bennet


4.96

42. Rosuvastatin +

Clopidogrel + Aspirin

Capsules


Rosuvastatin Calcium eq. to



pellets)



1

Capsule

M/s Synokem


M/s Aprica Healthcare

Pvt. Ltd.

11.53

43. Rosuvastatin +


Capsules





pellets)



1

Capsule

M/s Synokem


M/s Aprica Healthcare

Pvt. Ltd.

17.88

44. Memantine +

Donepezil Tablet

Each film coated tablet containing

Memantine Hydrochloride USP 5mg

Donepezil Hydrochloride IP 5mg

1 Tablet M/s Theon


M/s Emcure


9.93

45. Memantine +

Donepezil Tablet


Memantine Hydrochloride USP

10mg

Donepezil Hydrochloride IP 5mg

1 Tablet M/s Theon


M/s Emcure


12.56


46. Cilnidipine +

Telmisartan Tablet


Telmisartan IP 40mg

Cilnidipine 10 mg

1 Tablet M/s Akums Drugs &


M/s Abbott Healthcare

Pvt. Ltd.

7.77

47. Hyoscine

Butybromide +

Mefenamic Acid

Tablet


Hyoscine Butybromide IP 10 mg

Mefenamic Acid Tablet IP 250mg

1 Tablet M/s Zydus Healthcare

Ltd.

8.99

48. Rosuvastatin +

Aspirin +

Clopidogrel Capsule

(Rosulip Gold 10)





pellets)

Clopidogrel Bisulphate IP e. to


1

Capsule

M/s Synokem


M/s Cipla Ltd.

11.53

49. Rosuvastatin +

Aspirin +

Clopidogrel Capsule

(Rosulip Gold 20)





pellets)



1

Capsule

M/s Synokem


M/s Cipla Ltd.

17.88

50. Rosuvastatin +

Aspirin +

Clopidogrel Capsule

(Unistar Gold 10/75)





pellets)



1

Capsule

M/s Synokem


M/s Torrent

Pharmaceuticals Ltd

11.53

51. Rosuvastatin +

Aspirin +

Clopidogrel Capsule

(Unistar Gold 20/75)





pellets)



1

Capsule

M/s Synokem


M/s Torrent

Pharmaceuticals Ltd

17.88

52. Glimepiride +

Metformin HCL

tablet


containing

Glimepiride IP 0.5 mg

Metformin Hydrochloride IP 500 mg

(as prolonged released form)

1 Tablet M/s Windlas Biotech

Pvt. Ltd. / M/s Glenmark


3.77

53. Telmisartan +

Metoprolol Tablet

(Telmiprime Beta 25)

Each sustain release tablet containing

Telmisartan 40mg

Metoprolol 25 mg

1 Tablet M/s Bioaltus


Ltd. / M/s Primus

Remedies Pvt. Ltd.

7.58

54. Telmisartan +

Metoprolol Tablet

(Telmiprime Beta 50)

Each sustain release tablet containing

Telmisartan 40mg

Metoprolol 50 mg

1 Tablet M/s Bioaltus


Ltd. / M/s Primus

Remedies Pvt. Ltd.

9.10

55. Atorvastatin +


Capsule



Atorvastatin 20 mg (as pellets)

1

Capsule

M/s Synokem


M/s Zydus Healthcare

5.22



pellets)



Ltd. and

M/s Tristar Formulations

Pvt. Ltd. / M/s Zydus

Healthcare Ltd.

56. Atorvastatin +


Capsule



Atorvastatin 10 mg (as pellets)


pellets)



1

Capsule

M/s Synokem


M/s Zydus Healthcare

Ltd. and

M/s Tristar Formulations

Pvt. Ltd. / M/s Zydus

Healthcare Ltd.

3.86

57. Methylcobalamin +

Metformin Tablet

(Glycomet 500 MC)



(As SR form)

Methylcobalamin J.P. 750mcg

1 Tablet M/s Aeon Formulations

Pvt. Ltd. / M/s USV Pvt.

Ltd.

5.45

58. Methylcobalamin +

Metformin Tablet

(Glycomet 1000 MC)


Metformin Hydrochloride IP

1000mg (As SR form)

Methylcobalamin J.P. 750mcg

1 Tablet M/s Aeon Formulations

Pvt. Ltd. / M/s USV Pvt.

Ltd.

7.97


Folic Acid + Zinc

Sulphate Tablet

(Provikon-Fe)


Ferrous Ascorbate eq. to elemental

iron 100mg

Folic Acid IP 1.5mg

Zinc Sulphate Monohydrate eq. to

elemental Zinc 22.5mg

1 Tablet M/s Pharmafabrikon 6.22


Folic Acid

Suspension

(Provikon-Fe)

Each 5ml contains:


iron 30mg

Folic Acid IP 550mcg

1 ML M/s Pharmafabrikon 0.744

61. Acelofenac +

Paracetamol Tablet

(Winace)


Acelofenac IP 100 mg

Paracetamol IP 325 mg

1 Tablet M/s Windlas Biotech

Pvt. Ltd. / M/s Win

Medicare Pvt. Ltd.

3.34

62. Diclofenac Sodium

Injection

Each ml injection contains:

Diclofenac Sodium IP 75 mg

Water for Injection Ip QS

1 ML

Pack

M/s Bennet


20.00

63. Telmisartan +

Amlodipine +


(CTD-Tam 6.25/40/5)


Telmisartan IP 40 mg


Amlodipine 5 mg

Chlorthalidone IP 6.25 mg

1 Tablet M/s Akum Drugs &

pharmaceuticals Ltd. /

M/s Ipca Laboratories

Ltd.

8.62

64. Telmisartan +

Amlodipine +


(CTD-Tam 12.5/40/5)




Amlodipine 5 mg





Ltd.

8.75

65. Telmisartan +

Amlodipine +


(CTD-Tam 6.25/80/5)




Amlodipine 5 mg





Ltd.

14.40


66. Telmisartan +

Amlodipine +


(CTD-Tam 12.5/80/5)




Amlodipine 5 mg





Ltd.

14.00

67. Telmisartan +

Amlodipine +


(Telvas 3D CT 80)




Amlodipine 5 mg




M/s Aristo


Ltd.

14.12

68. Telmisartan +

Amlodipine +


(Telvas 3D CT 40)




Amlodipine 5 mg




M/s Aristo


Ltd.

8.91

69. Telmisartan +

Cilnidipine +


(CTD-TC 6.25)



Cilnidipine IP 10 mg





Ltd.

10.16

70. PEG L-Asparginase

Injection

Each 5 ml vial injection contains:

PEG L-Asparginase Injection 750

IU/ml

5

ML/Vial

M/s Virchow Biotech

Pvt. Ltd. / M/s Cadila

Pharmaceuticals Ltd

38730.74

71. PEG L-Asparginase

Injection

Each 5 ml vial injection contains:

PEG L-Asparginase Injection 750

IU/ml

5

ML/Vial

M/s Cadila Healthcare

Ltd.

38730.74


Folic Acid +

Cyanocobalamin +

Pyridoxine +

Cholecalciferol tablet



iron 100mg

Folic Acid IP 1.5 mg

Cyanocobalamin (Vitamin B12) IP

7.5mcg

Pyridoxine Hydrochloride (Vitamin

B6) IP 1.5 mg

Cholecalciferol (Vitamin D3) IP

1000IU

1 Tablet M/s Tirupati Medicare

Ltd. / M/s Cadila

Healthcare Ltd.

9.44

Note:

(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the

DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to

the Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned

manufacturer in accordance with the retail price specified in column (6) of the above table as per

provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in

Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS

and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the

supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the


premises where he carries on business in a manner so as to be easily accessible to any person wishing

to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as

mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision

as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements

as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission

from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the

concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price

notification and notes specified hereinabove, then the concerned manufacturer/marketing company

shall be liable to deposit the overcharged amount along with the interest thereon under the provisions

of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above

table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the

above said date of notification, stand(s) superseded.

[PN/191/59/2018/F/F. No. 8(59)/2018/D.P./NPPA-Div.-II]

BALJIT SINGH, Assistant Director

आदशे ubZ fnYyh] 13 vxLr] 2018

dk-vk- 3983¼v½.—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS”k/k ¼dher fu;a=.k½ vkns’k] 2013 ds iSjk 4,

6, 10, 11, 14, 16, 17 vkSj 18 }kjk iznRr ‘kfDr;ksa dk iz;ksx djrs gq, vkSj lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½ uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ”V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa Øe’k% rRLFkkuh izfof”V;ksa esa fofufnZ”V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof”V esa fofufnZ”V vuqlwfpr fofufeZfr;ksa esa ls izR;sd ij ykxw oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gS%

lkj.kh

dz-la-

vuqlwfpr fofufeZfr dk uke

[kqjkd :i ,oa izcyrk

bdkbZ vf/kdre dher ¼#-½

iqufoZyksdu vkns’k la- ,oa rkjh[k

ekStwnk dk- vk- la- ,oa rkjh[k

(1) (2) (3) (4) (5) (6) (7)

1. ,fe;ksMksjsu batsD’ku 50 fexzk-@fefy-

1 fefy- 20.94 31015/18/2016-

ihvkbZ-I ewY; fu/kkZj.k dh rkjh[k

29.05.2018

1461(v) fnukad 02.04.2018

(Ø-la- 34)

2. ,EQksVsfjflu ch fyfiM@fyikslksey

batsD’ku ds fy, ikmMj 50 fexzk-

izfr iSd 3844.83 31015/18/2018-


08.06.2018

1461(v) fnukad 02.04.2018

(Ø-la- 52)

3. jsuhfVfMu vksjy fybZD;wM 75 fexzk-@5 fefy-

1 fefy- 0.68 31015/78/2016-


08.06.2018

1461(v) fnukad 02.04.2018

(Ø-la- 703)


uksV %

¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klwfpr dh xbZ vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd dher ij vuqlwfpr fofufeZfr;ksa ds czkaMsM ;k tsusfjd ;k nksuksa :ikarjksa dks csp jgs vuqlwfpr fofufeZfr;ksa ds lHkh fofuekZrk] mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd lHkh ,slh fofufeZr;ksa dh dher dk v/kkseq[kh la’kks/ku djsaxsA

¼[k½ mi;qZDr lkj.kh ¼/ku oLrq ,oa lsok dj] tks ykxw gS] ;fn dksbZ gS½ ds LraHk ¼5½ esa fofufnZ”V vf/kdre ewY; dh vis{kk de [kqnjk ewY; okyh Åij of.kZr vuqlwfpr fofufeZfr;ksa ds lHkh ekStwnk fofuekZrk Mhihlhvks] 2013 ds iSjk 13¼2½ ds vuqlkj oLrq ,oa lsok dj ds dk;kZUo;u ij mRikn ‘kqYd vkSj djksa ds varj ds dkj.k vf/kdre [kqnjk ewY; esa gqbZ o`f) ds vykok ekStwnk vf/kdre [kqnjk ewY; dks fujarj cuk, j[ksaxsA

¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA

¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr lEcfU/kr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ&V esa vf/klwpuk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks ,d ewY; lwph tkjh djsa rFkk mldh dkWih jkT; vkS”kf/k fu;a=dksa vkSj fofuekZrk forjdksa dks tkjh djsaA

¼M+½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjksckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA

4. eSVªksfuMktksy xksyh 200 fexzk-

1 xksyh 0.43 31015/78/2016-


08.06.2018

1461(v) fnukad 02.04.2018

(Ø-la- 553)

5. eSVªksfuMktksy xksyh 400 fexzk-

1 xksyh 0.80 31015/78/2016-


08.06.2018

1461(v) fnukad 02.04.2018

(Ø-la- 554)

6. lsoksQ~ywjsu bugsys'ku 1 fefy- 28.07 31015/95/2017-


29.05.2018

vkSj

31015/103/2017-


22.06.2018

1461(v) fnukad 02.04.2018

(Ø-la- 734)

7. vkWDlkfyIysfVu batsD’ku 50 fexzk-

izfr iSd 2439.44 31015/105/2017-


22.06.2018

1461(v) fnukad 02.04.2018

(Ø-la- 597)

8. DyksVªhektksy Øhe 1% 1 xzke 2.73 31015/19/2017-


10.01.2018

1461(v) fnukad 02.04.2018

(Ø-la- 206)

9. MsDlVªku&40 batsD’ku 10% 1 fefy- 0.80 31015/03/2017-


24.08.2018

1461(v) fnukad 02.04.2018

(Ø-la- 246)


¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 2¼;w½ ds vuqlkj vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls ,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA

¼N½ mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds lwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA

¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds iSdksa dh vf/kdre dher fu;r gksus ds ifj.kkeLo:i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn dksbZ gks] tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh vf/kØe.k gks tk;saxsA

[dka-la-@191@59/2018@,Q@Qk- la0 8¼59½@2018@Mhih@,uihih,&fMoh-II]


ORDER


S.O. 3983(E).—In implementation of directions given in line with review orders issued by the

Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed

by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of

the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013,

read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the

Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the

Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority)

specified in the Column (7) of the table regarding formulation specified in mentioned in the table in so far as

it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be

done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes/revises the price

as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax

applicable, if any, in respect of the Scheduled formulation(s) specified in the corresponding entry in column

(2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding

entries in columns (3) and (4) thereof: TABLE

Sl.

No.

Name of the

Scheduled

Formulation

Dosage form

& Strength

Unit Ceiling

Price

(Rs.)

Review Order

number and date

Existing SO number

and date

(1) (2) (3) (4) (5) (6) (7)

1. Amiodarone Injection

50mg/ml

1 ML 20.94 31015/18/2016-PI.I

dated 29.5.2018

1461(E) dated

02.04.2018

(at Sl. No. 34)

2. Amphotericin B

Lipid/Liposomal

Powder for

Injection 50mg

Each Pack 3844.83 31015/18/2018-

Pricing dated

08.6.2018

1461(E) dated

02.04.2018

(at Sl. No. 52)

3. Ranitidine Oral liquid

75mg/5ml

1 ML 0.68 31015/78/2016-PI.I

dated 08.6.2018

1461(E) dated

02.04.2018

(at Sl. No. 703)


Note:

(a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled

formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and

notified by the Government, shall revise the prices of all such formulations downward not exceeding the

ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the

ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall

continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the

Government on the ceiling price mentioned in column (5) of the above said table.

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in

accordance with the ceiling price specified in column (5) of the above table as per provisions contained in

paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V

from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a

copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary

price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on

business in a manner so as to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the

above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall

apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the

DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in

respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,

2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled

formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or

import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to

the intended date of discontinuation.

4. Metronidazole Tablet 200mg 1 Tablet 0.43 31015/78/2016-PI.I

dated 08.6.2018

1461(E) dated

02.04.2018

(at Sl. No. 553)

5. Metronidazole Tablet 400mg 1 Tablet 0.80 31015/78/2016-PI.I

dated 08.6.2018

1461(E) dated

02.04.2018

(at Sl. No. 554)

6. Sevoflurane Inhalation 1 ML 28.07 31015/95/2017-

Pricing dated

29.5.2018

&

31015/103/2017-

Pricing dated

22.6.2018

1461(E) dated

02.04.2018

(at Sl. No. 734)

7. Oxaliplatin Injection

50mg.

Each Pack 2439.44 31015/105/2017-

Pricing dated

22.6.2018

1461(E) dated

02.04.2018

(at Sl. No. 597)

8. Clotrimazole Cream 1% 1 GM 2.73 31015/19/2017-

Pricing dated

10.01.2018

1461(E) dated

02.04.2018

(at Sl. No. 206)

9. Dextran-40 Injection 10% 1 ML 0.80 31015/3/2017-Pricing

dated 24.08.2017

1461(E) dated

02.04.2018

(at Sl. No. 246)


(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to

deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices

Control) Order, 2013 read with Essential Commodities Act, 1955.

(i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in

this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of

notification, stand(s) superseded.

[PN/191/59/2018/F /F. No. 8(59)/2018/D.P./NPPA-Div.-II]


vkns’k


dk-vk- 3984¼v½.—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼8½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA

lkj.kh

Ø-la-

fofufeZfr dk uke [kqjkd :i ,oa izcyrk bdkbZ [kqnjk ewY;

iqufoZyksdu vkns’k la- ,oa rkjh[k

ekStwnk dk- vk- la- ,oa rkjh[k

fofuekZrk vkSj foi.ku daiuh

(1) (2) (3) (4) (5) (6) (7) (8)

1. VsyfelkVZu $ ,EyksfMikbu xksyh ¼fVxkVsy ,,e 40½

izR;sd fQYe fyfir xksyh esa% VsyfelkVZu vkbZih 40 fexzk-]

,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk-

1 xksyh 7.74 31015/07/2018-

ewY; fu/kkZj.k dh fnukad 29.05.2018

3915(v) fnukad

18.12.2017

(Ø-la- 39)

eSllZ lu QkekZ yscksjsVfjt fy-

2. VsyfelkVZu$ gkbMªksDyksjksfFk;ktkbM xksyh ¼fVxkVsy ,p 40½

izR;sd vfyfir xksyh esa%

VsyfelkVZu vkbZih 40 fexzk-] gkbMªksDyksjksfFk;ktkbM vkbZih 12-5 fexzk-

1 xksyh 8.36 31015/07/2018-


3915(v) fnukad

18.12.2017

(Ø-la- 55)


3. VsyfelkVZu $ gkbMªksDyksjksfFk;ktkbM xksyh ¼fVxkVsy ,p 80½

izR;sd vfyfir xksyh esa% VsyfelkVZu vkbZih 80 fexzk-] gkbMªksDyksjksfFk;ktkbM vkbZih 12-5 fexzk-

1 xksyh 13.3

5

31015/07/2018-


3915(v) fnukad

18.12.2017

(Ø-la- 56)


4. VsyfelkVZu $ ,EyksfMikbu xksyh ¼fVxkVsy ,,e,p 40½


VsyfelkVZu vkbZih 40 fexzk-]

,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- gkbMªksDyksjksfFk;ktkbM vkbZih 12-5 fexzk-

1 xksyh 8.33 31015/07/

2018-


3915(v) fnukad

18.12.2017

(Ø-la- 57)



5. VsyfelkVZu $ ,EyksfMikbu xksyh ¼fVxkVsy ,,ep 80½

izR;sd vfyfir xksyh esa% VsyfelkVZu vkbZih 80 fexzk-]

,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- gkbMªksDyksjksfFk;ktkbM vkbZih 12-5 fexzk-

1 xksyh 13.0

6

31015/07/2018-


3915(v) fnukad

18.12.2017

(Ø-la- 58)


6. jkstqokLVkfVu $ ,fLifju DyksfiMksxzsy dSIlwy ¼jkstqdksj xksYM 10½

izR;sd gkMZ tsykVkbu dSIlwy esa%

jkstqokLVkfVu dSfY’k;e vkbZih ds cjkcj jkstqokLVkfVu 10 fexzk- ¼isysVl es½]

,fLifju vkbZih 75 fexzk- ¼xkLVªks jsfllVsaV isySVl esa½] DyksfiMksxzsy ckbZlYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼isysVl esa½

1 dSIlwy 11.7

0

31015/20/2018-


544(v) fnukad

06.02.2018

(Ø-la- 26)

eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ VkWjsaV QkekZL;wfVdYl fy-

7. lsfQDlhe $ vksQ~yksDlklhu xksyh ¼LVkulsQ&vks Iyl½

izR;sd fQYe fyfir xksyh esa% lsfQDlhe VªhgkbMªsV ds cjkcj lsfQDlhe ,ugkbMªkst vkbZih 200 fexzk-] vksQ~yksDlklhu vkbZih 200 fexzk-

1 xksyh 10.5

9

31015/17/2018-


270(E)

dated

16.01.2018

(at Sl. No.

27)

eSllZ Fksvksu QkekZL;wfVdYl fy-@eSllZ lu QkekZL;wfVdYl baMLVªh;y fy-

8. VªkbZilhu $ czksesysu $ :VkslkbM $ fMDyksQsud xksyh ¼oksfyVªk butks½

izR;sd vkarfjd fyfir xksyh esa%

VªkbZilhu chih 48 fexzk-]

Czksesysu 90 fexzk-] :VkslkbM VªhgkbMªsV chih 100 fexzk- fMDyksQsud lksfM;e vkbZih 50 fexzk-

1 xksyh 14.1

0

31015/17/2018-


270(E)

dated

16.01.2018

(at Sl. No.

28)

eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ lu QkekZL;wfVdYl baMLVªht fy-

9. isjkflVkeksy $ MkbZlkbDyksekbu xksyh ¼islheksy Likl½


isjkflVkeksy vkbZih 500 fexzk-]

MkbZlkbDyksekbu gkbMªksDyksjkbM vkbZih 20 fexzk-

1 xksyh 1.78 31015/19/2018-


544(v) fnukad

06.02.2018

(Ø-la- 1)

eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ vkbZihlh, yscksjsVfjt fy-

10. isjkflVkeksy $ dSQhu xksyh ¼islheksy ,fDVo½

izR;sd fQYe fyfir xksyh esa%

isjkflVkeksy vkbZih 650 fexzk-]

dSQhu ,ugkbMªkst vkbZih 50 fexzk-

1 xksyh 2.36 31015/19/2018-


544(v) fnukad

06.02.2018

(Ø-la- 6)

eSllZ vkbZihlh, yscksjsVfjt fy-

11. VsyfelkVZu $ ,EyksfMikbu $ DyksjFkkfyMksu xksyh ¼fVxkVsy ,lh,p 40½

izR;sd fQYe fyfir xksyh esa%

VsyfelkVZu vkbZih 40 fexzk-] ,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- gkbMªksDyksjksfFk;ktkbM vkbZih 12-5 fexzk-

1 xksyh 9.00 31015/22/2018-


544(v) fnukad

06.02.2018

(Ø-la- 17)



uksV %

¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA

¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA

¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA

¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA

¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mi;qZDr tsusjfd@leku lajpuk okyk dksbZ Hkh czkaM@ lacaf/kr fofufeZfr;ksa dh izcyrk rFkk ljdkj }kjk fu/kkZfjr ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr [email protected] dEifu;ka tks vuqikyu djrh gSA

¼p½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA

[dka-la-@191@59/2018@,Q@Qk- la0 8¼59½@2018@Mhih@,uihih,&fMoh-II]


ORDER



Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed

by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and In exercise of

the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O.

1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of

India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of

India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the

Column (7) of the table, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby

fixes, the price as specified in column (5) of the table herein below as the retail price, exclusive of goods and

services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said

Table with the strength, unit and name of manufacturer & marketing company , as specified in the

corresponding entries in columns (3), (4) and (8) thereof;

TABLE

Sl.

No.

Name of the

Formulation

Dosage form &

Strength

Unit Retail

Price

(Rs.)

Review Order

number and

date

Existing SO

number &

date

Manufacturer

& Marketing

Company

respectively

(1) (2) (3) (4) (5) (6) (7) (8)

1. Telmisartan +

Amlodipine Tablet

(Tigatel AM 40)

Each film coated

tablet contains:


Amlodipine Besylate

IP eq. to Amlodipine

5mg

1 Tablet 7.74 31015/7/2018-

Pricing dated

29.5.2018

3915(E) dated

18.12.2017

(at Sl. No. 39)

M/s Sun Pharma

Laboratories

Limited

2. Telmisartan +

Hydrochlorothiazide

Tablet

Each uncoated tablet

contains:


1 Tablet 8.36 31015/7/2018-

Pricing dated

29.5.2018

3915(E) dated

18.12.2017

(at Sl. No. 55)

M/s Sun Pharma

Laboratories

Limited


(Tigatel H 40) Hydrochlorothiazide

IP 12.5mg

3. Telmisartan +

Hydrochlorothiazide

Tablet

(Tigatel H 80)


contains:


Hydrochlorothiazide

IP 12.5mg

1 Tablet 13.35 31015/7/2018-

Pricing dated

29.5.2018

3915(E) dated

18.12.2017

(at Sl. No. 56)

M/s Sun Pharma

Laboratories

Limited

4. Telmisartan +

Amlodipine Tablet

(Tigatel AMH 40)


contains:


Amlodipine Besylate

IP Eq. to Amlodipine

5mg,

Hydrochlorothiazide

IP 12.5mg

1 Tablet 8.33 31015/7/2018-

Pricing dated

29.5.2018

3915(E) dated

18.12.2017

(at Sl. No. 57)

M/s Sun Pharma

Laboratories

Limited

5. Telmisartan +

Amlodipine Tablet

(Tigatel AMH 80)


contains:


Amlodipine Besylate

IP Eq. to Amlodipine

5mg,

Hydrochlorothiazide

IP 12.5mg

1 Tablet 13.06 31015/7/2018-

Pricing dated

29.5.2018

3915(E) dated 18.12.2017

(at Sl. No. 58)

M/s Sun Pharma

Laboratories

Limited

6. Rosuvastatin +

Aspirin +

Clopidogrel Capsule

(Rozucor Gold 10)

Each Hard Gelatine

Capsule contains:

Rosuvastatin Calcium

IP eq. to

Rosuvastation 10mg

(As pellets),

Aspirin IP 75mg (As

Gastro - resistant

pellets),

Clopidogrel

Bisulphate IP eq. to

Clopidogrel 75mg (As

pellets)

1

Capsule

11.70 31015/20/2018-

Pricing dated

08.6.2018

544(E) dated

06.02.2018

(at Sl. No. 26)

M/s Synokem

Pharmaceuticals

Limited / M/s

Torrent

Pharmaceuticals

Limited

7. Cefixime +

Ofloxacin Tablet

(Stancef-O Plus)

Each film coated

tablet contains:

Cefixime Trihydrate

eq. to Cefixime

Anhydrous IP 200mg,

Ofloxacin IP 200mg

1 Tablet 10.59 31015/17/2018-

Pricing dated

22.6.2018

270(E) dated

16.01.2018

(at Sl. No. 27)

M/s Theon

Pharmaceuticals

Limited a/ M/s

Sun

Pharmaceutical

Industrial

Limited

8. Trypsin + Bromelain

+

Rutoside +

Diclofenac Tablet

(Volitra Enzo)

Each enteric coated

tablet contains:

Trypsin BP 48mg, Bromelain 90mg,

Rutoside Trihydrate

BP 100mg Diclofenac

Sodium IP 50mg

1 Tablet 14.10 31015/17/2018-

Pricing dated

22.6.2018

270(E) dated

16.01.2018

(at Sl. No. 28)

M/s Synokem

Pharmaceuticals

Limited / M/s

Sun

Pharmaceuticals

Industries

Limited

9. Paracetamol +

Dicyclomine Tablet

(Pacimol Spas)

Each Uncoated tablet

contains:

Paracetamol IP

500mg,

Dicyclomine

Hydrochloride IP 20 mg

1 Tablet 1.78 31015/19/2018-

Pricing dated

22.6.2018

544(E) dated

06.02.2018

(at Sl. No. 1)

M/s Akums

Drugs and

Pharmaceutical

Ltd. / M/s IPCA

Laboratories Ltd.

10. Paracetamol +

Caffeine Tablate

(Pacimol Active)

Each film coated

Tablet contains:

Paracetamol IP 650mg,

Caffeine Anhydrous

IP 50mg

1 Tablet 2.36 31015/19/2018-

Pricing dated

22.6.2018

544(E) dated

06.02.2018

(at Sl. No. 6)

M/s IPCA

Laboratories Ltd.


11. Telmisartan +

Amlodipine +

Chlorthalidone

Tablet

(Tigatel ACH 40)

Each film coated

tablet contains:


Amlodipine Besylate

IP eq. to Amlodipine

5mg, Chlorthalidone

IP 12.5mg

1 Tablet 9.00 31015/22/2018-

Pricing dated

26.6.2018

544(E) dated

06.02.2018

(at Sl. No. 17)

M/s Sun Pharma

Laboratories

Limited

Note:

(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the

DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to

the Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned

manufacturer in accordance with the retail price specified in column (6) of the above table as per

provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in

Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS

and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the

supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the

premises where he carries on business in a manner so as to be easily accessible to any person wishing

to consult the same.

(e) The above mentioned retail prices are applicable only to the manufacturer / marketeer as mentioned

above for generic / any brand of the same composition / strength of the subject formulations, subject

to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant

statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the

Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing

companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price

notification and notes specified hereinabove, then the concerned manufacturer/marketing company

shall be liable to deposit the overcharged amount along with the interest thereon under the provisions

of the DPCO, 2013 read with the Essential Commodities Act, 1955.



vkns’k


dk-vk- 3985¼v½.—tcfd vkS”k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½ vkns’k] 2013 ds iSjk 19 ds varxZr jlk;u ,oa moZjd ea=ky; }kjk tkjh dk0 vk0 3091¼v½ fnukad 20-09-2017 ds rgr ,vkbZvkslhMh&,MCY;w,lh,l dh QkesZfVd fjiksVZ esa lqlaxr foi.ku vk/kkfjr vkdM+ksa dh vuqifLFkfr esa ljdkjh [kjhn ,tsafl;ksa dh [kjhn dherksa ds vk/kkj ij ¼i½ Qsjl lkYV¼,½ $ Qksfyd ,flM¼ch½& 45 fexzk-¼,½ $ 400 ,elhth¼ch½ ¼ii½ Qsjl lkYV¼,½ $ Qksfyd ,flM¼ch½ &20 fexzk-¼,½ $ 100,elhth¼ch½@fefy- dh vf/kdre dher fu;r dh gSA dk0 vk0 1461¼v½ fnukad 02-04-2018 ds rgr vf/kdre ewY; dks MCY;wihvkbZ ds vk/kkj ij ifj’kksf/kr fd;k x;kA

02- tcfd dqN fuekZrkvksa us ,uihih, ls vf/kdre dherksa iqujh{k.k gsrq vuqjks/k fd;k gS %&

¼i½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 20 fexzk-¼,½ $ 100,elhth¼ch½@fefy- vksjy fyD;wbZM xksyh vkSj

¼ii½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 45 fexzk-¼,½ $ 400 ,elhth¼ch½ xksyh


;g crk;k x;k gS fd ,uihih, }kjk fu;r ewY; vO;ogk;Z gSA fuekZrkvksa us ;g Hkh nkok fd;k gS fd vkiwfrZ eq[;r% ,uvkj,p,e ds fy, gSA

03- tcfd] ,uihih, dh 191 oha izkf/kdj.k dh cSBd tks fd 08-08-2018 dks vk;ksftr gqbZ Fkh ftlesa fofHkUu fuekZrkvksaa ds ;kfpdkvksa vkSj f’kdk;krksa ds vk/kkj ij vkS”k/k ¼ewY; fu;a=.k½ vkns’k] 2013 ds iSjk 19 ds rgr vf/kdre ewY;@ifj’kksf/kr ewY; dks okil ysus dk fu.kZ; fy;k gSA

¼i½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 20 fexzk-¼,½ $ 100,elhth¼ch½@fefy- vksjy fyD;wbZM xksyh vkSj

¼ii½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 45 fexzk-¼,½ $ 400 ,elhth¼ch½ xksyh

07- vc] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 19 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] vf/klwpuk la[;k dk-vk- 1461¼v½ fnukad 02-04-2018 vkSj dk-vk- 3091¼v½ fnukad 20-09-2017 dks bl vf/klwpuk dh frfFk ls fuEufyf[kr lhek rd vkS”kf/k dh vf/kdre ewY; dks okil ysrh Gsa

Ø-la-

fofufeZfr

¼i½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 20 fexzk- ,yhesaVy vk;ju ¼,½ $ 100,elhth¼ch½@fefy- vksjy fyD;wbZM

¼ii½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 45 fexzk- ,yhesaVy vk;ju ¼,½ $ 400 ,elhth¼ch½ xksyh

vU; lHkh vf/kdre dhersa vkSj uksV izpkyu esa jgsaxs tc rd fo’ks”k :i ls la’kksf/kr@ifj’kksf/kr u gksA

[dka- la-@191@59/2018@,Q@Qk- la0 8¼59½@2018@Mhih@,uihih,&fMoh--II]


ORDER


S.O. 3985(E).—Whereas the National Pharmaceutical Pricing Authority(NPPA), Department of

Pharmaceuticals, Ministry of Chemical and Fertilizers has fixed the ceiling price under paragraph 19 of the Drug (Prices

Control) order 2013, of (i) Ferrous Salt (A) + Folic acid (B) – 45 mg(A) + 400 mcg(B) Tablet and (ii) Ferrous Salt (A) +

Folic acid (B) – 20 mg(A) + 100mcg(B)/ml vide notification number SO 3091(E) dated 20.09.2017 based on the

procurement prices of Government procurement agencies, in the absence of the relevant market based data in the

Pharmatrac report of AIOCD-AWACS. Further, the ceiling prices were revised on the basis of WPI vide SO 1461(E)

dated 2.4.2018.

02. Whereas some manufacturers have prayed to the NPPA for revisiting the ceiling prices of

(i) Ferrous Salt (A) + Folic acid (B) – 20 mg(A) + 100mcg(B)/ml Oral Liquid and

(ii) Ferrous Salt (A) + Folic acid (B) – 45 mg(A) + 400mcg(B) Tablet

as the price fixed by the NPPA are unviable. The manufacturers also claimed that the supply is mainly for NRHM.

06. Whereas the NPPA in its 191st Authority meeting held on 08-08-2018, decided that ceiling price may be

fixed/revised under para 19 of the DPCO 2013 considering the petition and grievances of various manufacturers decided

to withdraw the notification in respect of

(i) Ferrous Salt (A) + Folic acid (B) – 20 mg(A) + 100mcg(B)/ml Oral Liquid and

(ii) Ferrous Salt (A) + Folic acid (B) – 45 mg(A) + 400mcg(B) Tablet

07. Now, in exercise of the powers conferred by paragraphs 19 of the Drugs (Prices Control) Order, 2013, read with

S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the

Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA)

hereby withdraw the ceiling price notification number SO 1461(E) dated 2nd April 2018 and SO 3091(E) dated

20.09.2017, with effect from the date of this notification, to the extent it belong to following scheduled formulation.


Sl. No. Scheduled Formulation

(i) Ferrous Salt (A) + Folic acid (B) – 20 mg elemental iron (A) + 100mcg(B)/ml Oral Liquid

(ii) Ferrous Salt (A) + Folic acid (B) – 45 mg elemental iron (A) + 400mcg(B) Tablet

All the other ceiling prices and notes shall continue to be operation unless specifically amended/revised.



vkns’k


dk-vk- 3986¼v½.—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr fofufnZ”V vkns’kksa la- 31015@3@2018 ewY; fu/kkZj.k fnukad 29-05-2016 ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS”k/k ¼dher fu;a=.k½ vkns’k] 2013 ds iSjk 5, 11, vkSj 15 }kjk iznRr ‘kfDr;ksa dk iz;ksx djrs gq, fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) dk0 vk0 3947¼v½ lg ifBr ‘kqf) i= dk0 vk0 4041¼v½ rkjh[k 22-12-2017 dks ml lhek dh fofufeZfr;ksa rd jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½ [kqnjk dher ds vf/kdre ewY; dks okfil ysrh gS] ¼i½ esVQkWfeZu 500 xzke] fXyesfijkbM 1 fexzk- vkSj fivksfXyVktksu 15 fexzk- xksyh vkSj ¼ii½ esVQkWfeZu 500 xzke] fXyesfijkbM 2 fexzk- vkSj fivksfXyVktksu 15 fexzk- xksyh dk0 vk0 3947¼v½ lg ifBr ‘kqf) i= dk0 vk0 4041¼v½ rkjh[k 22-12-2017 Øe la[;k 14 vkSj 15 esa fofufnZ”V eSllZ ;wuhlu QkekZL;wfVdYl izk- fy- }kjk foi.ku ,oa fofufeZr [kqnjk dherksa dks okil ysrh gSA

dk0 vk0 3947¼v½ fnukad 20-12-2017 esa n’kkZbZ xbZ lHkh [kqnjk dhersa vkSj uksV izpkyu esa jgsaxs] tc rd fd fo’ks”k :i ls la’kksf/kr@ifj’kksf/kr u fd;k tk,A

[dka-la-@191@59/2018@,Q@Qk- la0 8¼59½@2018@Mhih@,uihih,&fMoh--II]


ORDER



Department of Pharmaceuticals (DOP) vide order(s) number 31015/3/2018-pricing dated 29.5.2018 passed by

the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the

powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with

S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10

th March, 2016 issued by the Government of

India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of

India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) SO 3947(E)

read with corrigendum SO 4041(E) dated 22.12.2017 to the extend it belong to the formulation specified

hereafter, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby withdraw the

fixation of retail price of (i) Metformin 500mg, Glimepiride 1mg & Pioglitazone 15mg Tablet and (ii)

Metformin 500mg, Glimepiride 2mg & Pioglitazone 15mg Tablet specified at serial number 14 and 15 of the

SO 3947(E) read with corrigendum SO 4041(E) dated 22.12.2017 marketed and manufactured by the M/s

Unison Pharmaceuticals Pvt. Ltd.

All the other retail prices specified in the SO 3947(E) dated 20.12.2017 and notes shall continue to be

operation unless specifically amended/revised.




vkns’k


dk-vk- 3987¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lg ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 19 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] us dk0 vk0 2668¼v½ rkjh[k 16 vxLr] 2017 }kjk tkjh vkFkksZisfMd ?kqVuk bEIykaVl ds fy, fu/kkZfjr vf/kdre dherksa dh iz;ksT;rk dks vxys ,d o”kZ dh vof/k ¼;kfu 15 vxLr] 2019 rd½ c<+kus dk fu.kZ; fy;k gS tc rd fd vU; jkti= vf/klwpuk }kjk la’kksf/kr u fd;k tk,A

[dka-la-@191@59/2018@,Q@Qk- la0 8¼59½@2018@Mhih@,uihih,&fMoh--II]


ORDER


S.O. 3987(E).—In exercise of the powers conferred by paragraph 19 of the Drugs (Prices Control)

Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued

by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing

Authority (hereinafter referred as NPPA), hereby decided that applicability of the ceiling prices fixed for

orthopaedic knee implants vide SO 2668(E) dated 16 Aug, 2017 shall be extended for a period of another one

year (i.e upto 15 Aug, 2019), unless revised by another gazette notification.



Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064

and Published by the Controller of Publications, Delhi-110054.

Documents

EXTRAORDINARY Hkkx II—[k.M 3 mi&[k.M (ii) · 2018. 8. 18. · ¹Hkkx II µ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3 iSjkflVkeksy vkbZih 325 fexzk- 13. ,YcsuMktksy $ bojesLVhu xksyh